Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
Authors
Keywords
-
Journal
Hormones-International Journal of Endocrinology and Metabolism
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-09-29
DOI
10.1007/s42000-023-00493-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
- (2023) Mary E. Rinella et al. HEPATOLOGY
- Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study
- (2023) Shigenori Hiruma et al. DIABETES OBESITY & METABOLISM
- Challenges and opportunities in NASH drug development
- (2023) Stephen A. Harrison et al. NATURE MEDICINE
- Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )
- (2022) Olga Lavynenko et al. DIABETES OBESITY & METABOLISM
- Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
- (2022) Alessandro Mantovani et al. Lancet Gastroenterology & Hepatology
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
- (2022) Kenneth Cusi et al. Endocrine Practice
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Amalia Gastaldelli et al. Lancet Diabetes & Endocrinology
- Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- (2022) Qian Luo et al. Frontiers in Medicine
- The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials
- (2022) Fupeng Liu et al. PLoS One
- Liver, visceral and subcutaneous fat in men and women of South Asian and white European descent: a systematic review and meta-analysis of new and published data
- (2022) Stamatina Iliodromiti et al. DIABETOLOGIA
- The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
- (2022) Kiarash Riazi et al. Lancet Gastroenterology & Hepatology
- The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
- (2022) Sahar H. Elhini et al. Pharmaceuticals
- Combined EXENatide and DApagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycemic control in patients with type 2 diabetes mellitus treated with metformin – EXENDA , a 24 week, prospective, randomized, placebo‐controlled pilot trial
- (2021) Jürgen Harreiter et al. DIABETES OBESITY & METABOLISM
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
- (2021) B. Gaborit et al. Cardiovascular Diabetology
- Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
- (2021) Nobuharu Tamaki et al. GUT
- Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
- (2021) Abdul M. Majzoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
- (2021) Apostolos Tsapas et al. DIABETES OBESITY & METABOLISM
- Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
- (2021) Giuseppe Della Pepa et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- (2021) Qiong Wei et al. Frontiers in Endocrinology
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
- (2021) Samit Ghosal et al. Scientific Reports
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2020) Ling-Yun Zhang et al. Clinics and Research in Hepatology and Gastroenterology
- CINeMA: An approach for assessing confidence in the results of a network meta-analysis
- (2020) Adriani Nikolakopoulou et al. PLOS MEDICINE
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
- (2020) Apostolos Tsapas et al. ANNALS OF INTERNAL MEDICINE
- Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
- (2020) Jonathan G. Stine et al. Clinical Gastroenterology and Hepatology
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
- (2020) Wen Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
- (2020) Shih-Chieh Shao et al. BMJ Open Diabetes Research & Care
- Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- (2020) Alessandro Mantovani et al. Metabolites
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
- (2019) Huub J. van Eyk et al. Cardiovascular Diabetology
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation
- (2019) Maurice B. Bizino et al. DIABETOLOGIA
- Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review
- (2018) Christopher J. Weir et al. BMC Medical Research Methodology
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study
- (2018) Niina Matikainen et al. DIABETES OBESITY & METABOLISM
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
- (2017) Tisha R Joy et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
- (2016) Anna Vanderheiden et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Ranking treatments in frequentist network meta-analysis works without resampling methods
- (2015) Gerta Rücker et al. BMC Medical Research Methodology
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
- (2015) Hiroyuki Kato et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of Vildagliptin on Hepatic Steatosis
- (2015) Mavin Macauley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes
- (2014) Yan Bi et al. ACTA DIABETOLOGICA
- Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis
- (2014) Gerta Rücker et al. STATISTICS IN MEDICINE
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study
- (2014) Joseph Beyene et al. Clinical Epidemiology
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews
- (2012) Rebecca M Turner et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
- (2012) J. P. T. Higgins et al. Research Synthesis Methods
- Network meta-analysis, electrical networks and graph theory
- (2012) Gerta Rücker Research Synthesis Methods
- Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
- (2011) Padma Sathyanarayana et al. Obesity
- Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes
- (2010) J. T. Jonker et al. DIABETES CARE
- Checking consistency in mixed treatment comparison meta-analysis
- (2010) S. Dias et al. STATISTICS IN MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started